Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CMPtIMSMS

Financiado

Cerrado

Cancer metabolic profiling through ion mobility and mass spectrometric based met...

Cancer metabolic profiling through ion mobility and mass spectrometric based methods Cancer is a leading cause of death and there is little doubt regarding the importance of its early detection, in order to reduce both mortality and healthcare costs. In this regard, metabolomics is becoming a popular approach on t... ver más

30/09/2014

ETH Zürich

45K€

Presupuesto del proyecto: 45K€

Líder del proyecto

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-09-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ETH Zürich

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BREATH Characterization of biomarkers in breath of lung and breast... 171K€ Cerrado

CTQ2015-64402-C2-1-R NUEVAS PLATAFORMAS DE MULTIPLEXADO ELECTROANALITICAS PARA LA... 249K€ Cerrado

PID2021-126543OB-C22 PROCESADO DE SEÑAL EN METABOLOMICA CUANTITATIVA DIRIGIDA Y D... 182K€ Cerrado

PID2021-126543OB-C21 PROCESADO DE SEÑAL Y APRENDIZAJE AUTOMATICO PARA CROMATOGRAF... 200K€ Cerrado

CTQ2015-64402-C2-2-R NUEVAS PLATAFORMAS DE MULTIPLEXADO ELECTROANALITICAS PARA LA... 105K€ Cerrado

AURORAX Advancing cancer detection through metabolism based diagnost... 3M€ Cerrado

Líder del proyecto

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 45K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is a leading cause of death and there is little doubt regarding the importance of its early detection, in order to reduce both mortality and healthcare costs. In this regard, metabolomics is becoming a popular approach on the prowl for early diagnosis of cancer. Because biomarker discovery requires the analysis of numerous samples of high complexity, the development of high-throughput analytical platforms is of great interest. One such technology is ion mobility-mass spectrometry (IMS-MS). However, interfacing traditional drift-tube IMS with commercial MS requires substantial modifications of the latter, precluding its rapid expansion in metabolomic studies. Alternatively, differential mobility analyzers (DMA) are more easily combinable with commercial MS. We propose here to use a DMA-MS system to interrogate the metabolic phenotype of lung cancer tissue extracts. Complementarily to this plan, we intend to execute a second research strategy. Exhaled breath provides a continuous window to the biochemical activity within a person, and so holds promise as a diagnostic tool. However, in spite of the important milestones achieved following different approaches during the recent years, several issues remain to be solved before breath analysis may become a routine cancer screening method. Recently we have shown that with simple modifications, commercial mass spectrometers can sense in real time novel metabolites (e.g. glucose) in breath than previously detected. Here, we propose to employ this technology to compare the breath metabolic profiles of control subjects and cancer patients; and cancer patients before and after tumor removal. The aims are: (i) to advance in the development of alternative analytical platforms in metabolomics, (ii) to increase the knowledge of the still poorly understood underlying mechanisms of lung cancer development and progression and (iii) to determine potential biomarkers in breath of lung cancer patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores